Why access to Aduhelm won’t improve health equity
After CMS restricted access to Aduhelm, Biogen and the Alzheimer's Association called the decision discriminatory. Here's why we're skeptical... More
What’s in the Congressional drug pricing report?
A recently-released Congressional committee report on drug prices reveals some outrageous business practices by pharma -- here's what they found. More
How a pharma-led campaign to lower a diabetes treatment target put seniors at risk
A recent Reuters investigation found that a campaign to lower the A1c target for diabetes was driven largely by pharmaceutical companies, to create a bigger market for their new blood sugar-lowering drugs. More
High-priced cancer drugs are driving pharma revenue
Has pharma cracked the secret code to profit through cancer drugs? A recent study takes a closer look at the impact of cancer drug prices on pharma revenues. More
Drug advertisements that scare
Despite larger health threats consuming the nation this year, pharma did not let up on their fear-mongering advertisements. Check out a few of the scariest-- if you dare! More
Is the price of remdesivir too high or too low?
Experts weigh in on the recently revealed price of Covid-19 drug remdesivir. More
Remdesivir report sparks more debate on drug price value
How much should remdesivir cost? This question puts two drug-value organizations at odds. More
Are high drug prices buying us the most effective treatments?
The pharmaceutical industry often justifies high drug prices by claiming that they create more innovation, but two recent studies find that drug costs and clinical benefit are often not related. More
What we lose by promoting unproven Covid-19 remedies
Breaking down the flawed logic of "What do we have to lose?" when it comes to untested Covid-19 treatments. More
The true cost of “free” samples
Many physicians see drug samples as a benefit, because they can give pills to patients who may not be able to afford the medication otherwise. But are these "free" samples really free? More